Technical Analysis for CBIO - Catalyst Inc.

Grade Last Price % Change Price Change
grade D 8.7 -0.23% -0.02
CBIO closed down 0.23 percent on Thursday, April 18, 2019, on 64 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CBIO trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
50 DMA Resistance Bearish -0.23%
Wide Bands Range Expansion -0.23%
Down 3 Days in a Row Weakness -0.23%
Down 4 Days in a Row Weakness -0.23%
Down 5 Days in a Row Weakness -0.23%

Older signals for CBIO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Catalyst Biosciences, Inc., a biopharmaceutical company, focuses on discovering and developing novel biopharmaceutical products based on engineered human proteases. The company designs its proteases to promote hemostasis and to prevent inflammation. Its pipeline of protease therapeutics include CB 813d/PF-05280602, an engineered Factor VIIa drug candidate that completed a Phase 1 clinical trial evaluating safety and tolerability, as well as pharmacokinetics, pharmacodynamics, and coagulation activity. The company's pre-clinical development stage drugs comprise CB 2679d/ISU 304, a next-generation Factor IX drug for the treatment of hemophilia B inhibitor patients; and an engineered Factor Xa for hemophilia and the control of bleeding in non-hemophilia patients. It also develops factor C3 for the prevention of renal delayed graft function and the treatment of dry age-related macular degeneration. Catalyst Biosciences, Inc. is headquartered in South San Francisco, California.
Biopharmaceutical Inflammation Molecular Biology Cell Biology Anatomy Pharmacokinetics Macular Degeneration Hemophilia Treatment Of Hemophilia Coagulation System Biopharmaceutical Products Coagulation Pharmacodynamics Factor X
Is CBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.95
52 Week Low 6.2
Average Volume 186,316
200-Day Moving Average 9.6386
50-Day Moving Average 8.8622
20-Day Moving Average 9.067
10-Day Moving Average 9.448
Average True Range 0.5494
ADX 15.77
+DI 21.3688
-DI 23.3631
Chandelier Exit (Long, 3 ATRs ) 9.1918
Chandelier Exit (Short, 3 ATRs ) 9.4482
Upper Bollinger Band 10.4597
Lower Bollinger Band 7.6743
Percent B (%b) 0.37
BandWidth 30.720194
MACD Line 0.0473
MACD Signal Line 0.1596
MACD Histogram -0.1123
Fundamentals Value
Market Cap 37.49 Million
Num Shares 4.31 Million
EPS -14.07
Price-to-Earnings (P/E) Ratio -0.62
Price-to-Sales 35.66
Price-to-Book 0.66
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.12
Resistance 3 (R3) 9.12 8.98 9.05
Resistance 2 (R2) 8.98 8.87 8.98 9.03
Resistance 1 (R1) 8.84 8.81 8.84 8.84 9.00
Pivot Point 8.70 8.70 8.70 8.70 8.70
Support 1 (S1) 8.56 8.59 8.56 8.56 8.40
Support 2 (S2) 8.42 8.53 8.42 8.37
Support 3 (S3) 8.28 8.42 8.35
Support 4 (S4) 8.28